SCHEDULE 13G/A: Janus Henderson Group Discloses 8.5% Stake in Vaxcyte Inc. Common Stock

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 8.5% of Vaxcyte Inc.'s common stock as of December 31, 2024.

Summary

• Janus Henderson Group plc filed an Amendment No. 5 to Schedule 13G concerning its beneficial ownership in VAXCYTE, INC.
• As of December 31, 2024, Janus Henderson Group plc beneficially owns an aggregate of 10,575,363 shares of VAXCYTE, INC. common stock.
• This ownership represents 8.5% of the total class of VAXCYTE, INC. common stock.
• Janus Henderson Group plc holds both shared voting power and shared dispositive power over these 10,575,363 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Janus Henderson Group plc is classified as an Investment Adviser (IA) and a Parent Holding Company (HC), with subsidiaries like JHIUS, JHIUKL, and JHIAIFML acting as registered investment advisers to Managed Portfolios.

Sentiment

Score: 5

Explanation: The document is a factual report of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the issuer's performance or outlook. It simply states an ownership position.

Positives

• The disclosure of a significant institutional investment by Janus Henderson Group plc, a major asset manager, may signal confidence in Vaxcyte Inc.'s prospects.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive, investment-oriented stake.

Future Outlook

NA

Industry Context

This filing represents a routine regulatory disclosure of a significant institutional ownership stake in a publicly traded company, Vaxcyte Inc., which operates in the biotechnology or pharmaceutical sector. Such disclosures are standard for large asset management firms like Janus Henderson Group plc as part of their portfolio management and compliance obligations. It does not offer specific insights into Vaxcyte's industry position or competitive landscape beyond confirming a substantial investment by a major financial institution.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor like Janus Henderson Group plc holding an 8.5% stake may be viewed positively, signaling institutional confidence in Vaxcyte Inc.

Key Dates

Keywords

SEC filing, Schedule 13G, Beneficial ownership, VAXCYTE INC., Janus Henderson Group plc, Common Stock, Institutional investment, Ownership stake, Investment adviser